MRDR research output and activities: publications, presentations and annual reports
Lim SL, Wellard C, Moore E, Harrison SJ, Hang Q, Ho J, Rajagopal R, Spencer A. Intern Med J. 2023 Dec 27. doi: 10.1111/imj.16277..
Lim KJ, Wellard C, Talaulikar D, Tan JL, Loh J, Puvanakumar P, Kuzich JA, Ho M, Murphy M, Zeglinas N, Low MS, Routledge D, Lim AB, Gibbs, SD, Quach H, Morgan S, Moore E and Ninkovic S. EJHaem. 2023 Jul;4(3): e639-e646. doi:10.1002/jha2.742
Tan JLC, Wellard C, Moore EM, Mollee P, Rajagopal R, Quach H, Harrison SJ, McDonald E, Ho PJ, Prince HM, Augustson BM, Campbell P, McQuilten ZK, Wood EM, Spencer A, and Myeloma and Related Diseases Registry Investigators. Br J Haematol. 2023 Jan;200(2):e17-e21. doi:10.1111/bjh.18536.
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison SJ, Ho PJ, King T, Quach H, Mollee P, B Rosengarten, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Br J Haematol. https://doi.org/10.1111/bjh.18324. Published:June 9, 2022.
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM, Blacklock H, Wellard C, Spearing R, Merriman L, Poplar S, George A, Baker B, Chan H, McQuilten ZK, Wood EM, Spencer A, MRDR investigators. Clin Lymphoma Myeloma Leuk. 2022 Apr 8: S2152-2650(22)00118-5. doi: 10.1016/j.clml.2022.04.004. Published:April 8, 2022.
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Eur J Haematol. Published:June 15, 2021.
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealad myeloma and related diseases registry (MRDR).
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bone Marrow Transplant. Published: May 19, 2021.
The Myeloma Landscape in Australia and New Zealand (ANZ): The First Eight Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K, Wellard C, Moore EM, McQuilten Z, Augustson B, Blacklock H, Harrison SH, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood EM, Spencer A, on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry. Clin Lymphoma Myeloma Leuk. Published:January 29, 2021.
Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial.
Moore EM, King TA, Wood EM, Ruseckaite R, Klarica D, Spencer A, Ho PJ, Quach H, Prince HM, McQuilten ZK. Am J Hematol. 2020 Jul;95(7):e178-181.
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424.
Myeloma in the Real World: What Is Really Happening?
Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.
Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, Ho J, Horvath N, King T, McNeil J, Mollee P, Quach H, Reid CM, Rosengarten B, Walker P, Spencer A. BMC Med Res Methodol. 2016 Nov 9;16(1):151.
- Oral presentation:
D. Wong et al., Cell free MYC DNA copy number identifies high-risk smoldering myeloma and newly diagnosed multiple myeloma.
- Poster presentations:
- Annual Breakfast Meeting:
- Poster Presentations:
- Poster Presentations:
M Cantley et al., CTX-1 as a blood-based biomarker to identify risk of progression from smouldering myeloma to multiple myeloma. (Oral)
S Lim et al., MRDR and AMaRC trials update. (Oral)
K Bergin et al., Australian data from the Myeloma and Related Disease Registry. (Oral)
J Tan et al., Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study. (Poster)
J Ng et al., Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries. (Poster)
M. Cantley et al., CTX-1 levels can predict individuals at high risk of progression from smouldering myeloma to multiple myeloma (Oral)
S. Lim et al., Continuing poor outlook for relapsed Australian Multiple Myeloma (MM) patients: Impact of limited available therapies (Oral)
K. Chai et al., Infection patterns and outcomes in patients with newly diagnosed multiple myeloma: Preliminary results from the IMPROVE (Immunoglobulins in myeloma patients: research into outcomes, variation in practice and epidemiology) Cohort Study (Poster)
K. Chai et al., Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR (Poster)
A. Irving et al., Epidemiological Modelling of Australian Patients with Myeloma, EpiMAP Myeloma (Poster)
J. Tan et al., Validation of the second revision of the International Staging System in a real-world myeloma population (R2-ISS): A Myeloma and Related Diseases Registry (MRDR) Study (Poster)
J. Ng. et al., Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and the Asia-Pacific Myeloma and Related Diseases Registries (Poster)
J. Ng. et al., Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries. (Poster)
J. Tan et al., Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study. (Poster)
K Chai et al., Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR (e-Poster)
A. Tedjaseputra et al., Long-term follow-up of tandem autologous plus non-myeloablative allogeneic transplant in relapsed myeloma: An Australian report from the Alfred & the Myeloma and Related Diseases Registry (MRDR) (Poster)
ISOQOL 28th Annual Conference, Oct 2021 (virtual)
E Moore: EQ-5D-5L utility scores at diagnosis and association with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Oral presentation)
MRDR Annual Investigator and Interest Group Meeting (live webinar, 2021)
Blood 2021, (virtual conference)
PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR (Oral presentation)
A Tedjaseputra, Tandem autologous-allogeneic-SCT in relapsed multiple myeloma: a joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR) (poster)
R Cao, Causes of death in multiple myeloma in Australia: results from the Australian and New Zealand Myeloma and Related Diseases Registry (Narrated poster)
E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Narrated poster)
International Myeloma Workshop, Sep 2021 (hybrid conference, Vienna-based)
PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) (Narrated poster)
A Tedjaseputra, Tandem autologous + non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma: an Australian joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR) (poster)
Nursing Symposium, IMW
E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Oral presentation)
Using PROMs ‘Down-under’ – Supported by ISOQOL, July 2021 (virtual Sydney-based conference)
Monash SPHPM Registry Meeting 2021
A Irving, EpiMAP Myeloma (Oral presentation)
ASH 2020 (virtual)
MRDR Annual Interest Group Meeting (held by webinar, during the 3rd NMW, Australia 2020)
3rd National Myeloma Workshop, Australia 2020 (virtual)
A. Spencer, Early disease progression identifies an ultra-high risk sub-group of newly diagnosed multiple myeloma – A report from the MRDR
J. Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR (Poster)
R. Cao, Infection is a major contributor to causes of death in multiple myeloma: results from the ANZ MRDR (Poster)
N. Khajornjiraphan, Outcomes of bortezomib vs lenalidomide in patients with NDMM ineligible for ASCT – initial results from the ANZ MRDR (Poster)
A. Jackson, Outcome of patients with multiple cytogenetic abnormalities at diagnosis: Results from the ANZ MRDR (Poster)
Monash SPHPM Registry Meeting 2020
Haematology Society of Taiwan Meeting 2020
European Haematology Association Congress 2020 (virtual)
Blood 2019, October, Perth, Australia
International Myeloma Workshop 2019, September, Boston, USA
E. Moore et al., Health-related quality of life at diagnosis in multiple myeloma: EQ-5D-5L results from the MRDR and comparison with an Australian population norm (Poster), Alfred Week, June 2019
E. Moore et al., Data with impact, Myeloma UK Patient Registry Stakeholder Workshop. London, April 2019
Inaugural Clinical Registries Summit, SPHPM, Monash, November 2018
Blood 2018, October, Brisbane
2nd National Myeloma Workshop, Yarra Valley, Australia, September 2018
A. Spencer. Real world outcomes from the Myeloma and Related Diseases Registry. 3rd Annual Educational Seminar, Myeloma Special Practice Network, HSANZ Nurses Group, Royal Adelaide Hospital: August 2018
E. Moore. News from the Myeloma and Related Diseases Registry. Registry Special Interest Group meeting, SPHPM, Monash: July 2018
E. Moore and T. King, Growth and outcomes of the Myeloma and Related Diseases Registry. Quality of Life Office meeting, University of Sydney, July 2018
E. Moore et al., Maturing data from the Australia and New Zealand Myeloma and Related Diseases Registry (Poster), Alfred week, The Alfred Hospital, June 2018
K. Bergin et al., Utilisation Rates of Upfront Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: a report on behalf of the MRDR (Poster), EBMT, Lisbon, March 2018
HAA 2017, November, Sydney
J. Ho, Renal impairment in myeloma: patient characteristics, treatment modalities, stem cell transplant & outcomes from the ANZ MRDR (Poster), European Haematology Association Congress, June 2017
A. Spencer, The myeloma and related diseases registry: a tool for practice improvement, Victorian Integrated Cancer Services Conference, Melbourne, May 2017
A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, May 2017
International Myeloma Workshop, New Delhi, February 2017
Talks including reference to or introduction of the MRDR:
E. Wood, Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 2016
HAA, Melbourne, November 2016
National Myeloma Workshop, Yarra Valley, Vic, September 2016
E. Moore, MRDR: Maturing data, HSANZ Nurses Group, Myeloma Special Practice Network Education Seminar, August 2016
E. Moore, MRDR: sustaining growth, Monash SPHPM Registry SIG, June 2016
A. Spencer, MRDR presentation to ALLG, ALLG Scientific Meeting, May 2016
B. Rosengarten, Myeloma Awareness Day Meeting, Sydney, May 2016
Talks including reference to or introduction of the MRDR:
E. Wood, Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 2015
A. Spencer, Korean Society of Hematology annual meeting, Seoul, November 2015
HAA, Adelaide October 2015
E. Moore et al., Real world management of multiple myeloma: Initial results from the Australia and New Zealand Myeloma and Related Diseases Registry (Poster), International Myeloma Workshop, Rome, September 2015
Talks including reference to or introduction of the MRDR:
A. Spencer, Myeloma Scientific Advisory Group, Myeloma Foundation Australia, Melbourne, Victoria
A. Spencer, MRDR Interest Group Meeting, HAA, Perth, Western Australia, October 2014
Talks including reference to or introduction of the MRDR:
A. Spencer HAA Investigator Meeting, Gold Coast, Queensland